Teva Slams Antitrust Claims In Azilect Patent Row

Law360, New York (February 21, 2013, 6:59 PM EST) -- Teva Pharmaceutical Industries Ltd. said its patent for its Parkinson’s disease drug Azilect is valid and would-be generic competitors are overreaching in claims that it broke antitrust laws to secure the patent through fraud and sham suits, according to a pretrial brief filed Wednesday in New Jersey federal court.

Teva slammed the antitrust and patent invalidity claims raised by generic drugmakers Watson Laboratories Inc., Mylan Pharmaceuticals Inc., Orchid Chemicals & Pharmaceuticals Ltd. and Apotex Corp., saying there is clear evidence that they infringed on Teva’s patent...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.